Fig. 3From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and TaiwanResponse rates for ACR20, ACR50, and ACR70 over time (FAS)Back to article page